PAM
BCRX icon

Paradigm Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Paradigm Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-11,200
Closed -$17.4K – 807
2013
Q2 		$17.4K Buy
+11,200
New +$19.3K ﹤0.01% 718

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Paradigm Asset Management's BCRX Position: Q3 2013 in Review

Paradigm Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2013, closing a stake of 11,200 shares — an estimated $17.4K sold.

Paradigm Asset Management first reported a position in BCRX in Q2 2013 and held it in 1 quarter. The position peaked at $17.4K in Q2 2013. 73 funds tracked by Wall St. Rank hold BCRX as of Q3 2013.

  • Paradigm Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Paradigm Asset Management sold 11,200 BioCryst Pharmaceuticals shares in Q3 2013, an estimated $17.4K.
  • Paradigm Asset Management first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Paradigm Asset Management's BioCryst Pharmaceuticals position peaked at $17.4K in Q2 2013.
  • 73 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2013.

Based on Paradigm Asset Management's 13F filing for Q3 2013, filed 30 Oct 2013.